Illumina Inc. (ILMN)
NASDAQ
Biotech
Genomics
Investment Thesis
Illumina is the Intel of genomics — the dominant sequencing infrastructure provider that every gene editing, drug discovery, and personalised medicine company depends on. A genome that cost $100M to sequence in 2001 costs $200 today. When it crosses $100, whole-genome sequencing becomes routine clinical standard. Illumina controls the instrument that drives that cost curve.
Key Drivers
- Installed Base: 22,000+ sequencing systems globally — razor-and-blade economics (instruments + consumables).
- NovaSeq X: New flagship platform targeting $1 genome; clinical adoption is the catalyst.
- Cancer Early Detection: GRAIL acquisition attempted (blocked by FTC); the multi-cancer early detection market remains a massive adjacent opportunity.
Risk Factors
- Competition: Element Biosciences, PacBio, and ONT are challenging on specific use cases.
- Post-COVID Lab Spending: Government and academic lab budgets normalised sharply post-2022.